ak 2123 has been researched along with nimorazole in 2 studies
| Studies (ak 2123) | Trials (ak 2123) | Recent Studies (post-2010) (ak 2123) | Studies (nimorazole) | Trials (nimorazole) | Recent Studies (post-2010) (nimorazole) |
|---|---|---|---|---|---|
| 52 | 8 | 5 | 106 | 29 | 35 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shibamoto, Y | 1 |
| Hori, H; Ito, M; Nagasawa, H; Ogino, H; Shibamoto, Y; Sugie, C; Suzuki, H; Uto, Y | 1 |
1 review(s) available for ak 2123 and nimorazole
| Article | Year |
|---|---|
[Contribution of radiation biology to the development of radiation therapy].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose Fractionation, Radiation; Humans; Imidazoles; Lung Neoplasms; Neoplasms; Nimorazole; Radiation-Sensitizing Agents; Triazoles | 1999 |
1 other study(ies) available for ak 2123 and nimorazole
| Article | Year |
|---|---|
Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Evaluation, Preclinical; Female; Mice; Nimorazole; Nitroimidazoles; Radiation Tolerance; Radiation-Sensitizing Agents; Treatment Outcome; Triazoles | 2005 |